The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

• On March 11, Arvinas announced topline results from the phase 3 VERITAC-2 Trial of Vepdegestrant Monotherapy versus Fulvestrant in adults with advanced or retastatic breast cancer. The company's stock fell around 53% over the past month and has a 52-week low of $7.91.
• RSI Value: 25.9
• ARVN Price Action: Shares of Arvinas fell 5.6% to close at $8.13 on Tuesday.

• Simulations Plus will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3. The company's stock fell around 19% over the past month and has a 52-week low of $24.00.
• RSI Value: 29.7
• SLP Price Action: Shares of Simulations Plus fell 3.2% to close at $24.72 on Tuesday.
• Benzinga Pro’s charting tool helped identify the trend in SLP stock.

• On March 21, Iovance Biotherapeutics reported inducement grants under NASDAQ listing rule 5635(c)(4). The company's stock fell around 35% over the past month and has a 52-week low of $3.42.
• RSI Value: 26.7
• IOVA Price Action: Shares of Iovance Biotherapeutics fell 4.1% to close at $3.48 on Tuesday.
• Benzinga Pro’s signals feature notified of a potential breakout in IOVA shares.